A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI

Interested in this Trial?

Contact Us

Trial Status Completed

Trial Identifier

NCT00299000

Condition

MPS VI, Mucopolysaccharidosis VI, Maroteaux-Lamy Syndrome

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

The purpose of the study is to evaluate the safety and efficacy of two dose levels of Naglazyme in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth.

Eligibility Criteria

Birth Sex

All

Age

Up to 1 Year

Healthy Volunteers

No

Drug/Treatment:

Naglazyme

Phase:

Phase 4

Study Type:

Interventional

Number of Participants:

4

Study Started:

2006-05

Study Updated:

2011-07-22

Trial Locations

  • Children's Hospital Los Angeles

    Los Angeles, California, United States

  • Children's Hospital Oakland

    Oakland, California, United States

  • Hospital Femme Mere Enfant Centre

    Lyon, , France

  • Hospital PediAtrico de Coimbra

    Coimbra, , Portugal

Inclusion Criteria

  • Signed informed consent by a parent or legal guardian
  • Parent or legal guardian willing and able to comply with all study procedures
  • Equal to or greater than 36 weeks estimated gestational age by physical exam at birth
  • Has a diagnosis of MPS VI based on a documented prenatal diagnosis or fibroblast or leukocyte N-acetylgalactosamine 4-sulfatase (ASB) enzyme activity level of less than 10% of the lower limit of the normal range of the measuring laboratory
  • Is less than one year of age
  • Has no evidence of skeletal dysplasia based on physical exam

Exclusion Criteria

  • Parent of legal guardian perceived to be unreliable or unavailable for study participation
  • Use of any investigational drug within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments
  • Has concurrent disease or condition that would interfere with study participation or safety (i.e., has previously undergone hematopoietic stem cell transplantation such as bone marrow or cord blood transplantation, or major organ transplantation)
  • Any condition that, in the view of the principle investigator, renders the subject at high risk from treatment compliance and/or completing the study
  • Has known hypersensitivity to Naglazyme
  • Has previously received Naglazym

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our clinical trials.

By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.

*required fields

"*" indicates required fields

This field is hidden when viewing the form
This field is hidden when viewing the form